Second Sight to Convene First Ever Retinal Prosthesis Users Summit at Retina International World Congress
2 Pages
English

Second Sight to Convene First Ever Retinal Prosthesis Users Summit at Retina International World Congress

Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

Description

Second Sight to Convene First Ever Retinal Prosthesis Users Summit at Retina International World Congress PR Newswire LAUSANNE, Switzerland, July 13, 2012 LAUSANNE, Switzerland, July 13, 2012 /PRNewswire/ -- ®12 Argus II Users to Meet and Attend the Congress in Hamburg Second Sight Medical Products, Inc., the world's only developer and manufacturer of an approved retinal prosthesis for the blind, is hosting a summit for users of the Argus II Retinal Prosthesis System to be held in conjunction with the Retina International World Congress this weekend (July 13 - 15) in Hamburg, Germany. Twelve (12) users will come together to see each other for the first time, share their experiences, and provide feedback on future product development for Second Sight. Users from the UK, France, Germany, Switzerland, and Italy are expected to attend. Additionally, the company is co-sponsoring a lunchtime symposium on electronic retinal implants on Saturday, July 14. In this session, Prof. Dr. med. Peter Walter (Universitäts-Augenklinik, RWTH Aachen, Germany), one of three surgeons in Germany to have implanted Argus II in patients to date, and Fatima Anaflous (Second Sight, Lausanne, Switzerland) will present the latest information on Argus II, Europe's only approved and commercially available retinal prosthesis.

Subjects

Informations

Published by
Reads 36
Language English
Second Sight to Convene First Ever Retinal
Prosthesis Users Summit at Retina
International World Congress
PR Newswire
LAUSANNE, Switzerland, July 13, 2012
LAUSANNE
,
Switzerland
,
July 13, 2012
/PRNewswire/ --
12 Argus
®
II Users to Meet and Attend the Congress in Hamburg
Second Sight Medical Products, Inc., the world's only developer and
manufacturer of an approved retinal prosthesis for the blind, is hosting a
summit for users of the Argus II Retinal Prosthesis System to be held in
conjunction with the Retina International World Congress this weekend (
July 13 -
15
) in
Hamburg, Germany
. Twelve (12) users will come together to see each
other for the first time, share their experiences, and provide feedback on
future product development for Second Sight. Users from the UK,
France
,
Germany
,
Switzerland
, and
Italy
are expected to attend.
Additionally, the company is co-sponsoring a lunchtime symposium on
electronic retinal implants on
Saturday, July 14
. In this session, Prof. Dr. med.
Peter Walter (Universitäts-Augenklinik, RWTH Aachen,
Germany
), one of three
surgeons in
Germany
to have implanted Argus II in patients to date, and Fatima
Anaflous (Second Sight,
Lausanne
,
Switzerland
) will present the latest
information on Argus II,
Europe's
only approved and commercially available
retinal prosthesis. Walter is excited about presenting long-term data from
participants in the company's clinical trials, which began in 2002 and include
patients that have used the implant for up to 8 years, and also the results from
commercial patients. "I started to work on retinal implants more than fifteen
years ago here in
Germany
because I knew we could and we should help blind
patients suffering from retinitis pigmentosa (RP). Today with Argus II, we can
finally offer a treatment to patients backed by many years of safety and
performance data". Anaflous, a low vision therapist, will present three years of
patient experience with integrating the Argus II in their daily lives and what it
means for these individuals. Second Sight will also host a booth in the exhibit
hall to field enquiries from doctors and prospective patients.
Argus II
is Second Sight's less invasive second generation implantable device
intended to treat blind people suffering from degenerative diseases of the
outer retina such as RP. The system works by converting video images
captured by a miniature camera, housed in the patient's glasses, into a series
of small electrical pulses that are transmitted wirelessly to an array of
electrodes on the surface of the retina (epi-retinal). These pulses are intended
to stimulate the retina's remaining cells resulting in the corresponding
perception of patterns of light in the brain. Patients then learn to interpret
these visual patterns thereby gaining some functional vision. Argus II was
tested in a single arm, controlled, prospective, multicenter international clinical
trial, the results of which were published in the April edition of the prestigious
journal,
Ophthalmology
, and showed that "The
Argus
ll prosthesis system is
reliable over the long term and provided benefit to implanted subjects during
this period … This demonstrates the ability of this retinal implant to provide
meaningful visual perception and usefulness to subjects blind as a result of end-
stage outer retinal degenerations."
Gregoire Cosendai, PhD, head of Second Sight's European subsidiary, added
"We warmly welcome the
Argus
ll users from across
Europe
to
Hamburg
to
share their experiences. We are looking forward to learning more about what is
important to them now and in the future for retinal prosthetics".
Second Sight Medical Products, Inc., located in
Los Angeles California
,
was founded in 1998 to create a retinal prosthesis to provide sight to
patients blinded from outer retinal degenerations, such as Retinitis
Pigmentosa. Through dedication and innovation, Second Sight's
mission is to develop, manufacture and market implantable visual
prosthetics to enable blind individuals to achieve greater
independence. European Headquarters are in
Lausanne
,
Switzerland
.Second Sight,
Argus
and the Second Sight logo are
registered trademarks of Second Sight Medical Products, Inc. Argus II
is not approved for commercial use in
the United States
; it is being
used in clinical trials under an FDA-approved Investigational Device
Exemption (IDE).
For more information please contact
Maura Arsiero (+41-21-693-91-01)
patients@2-sight.com
publicrelations@2-sight.com